Randomised controlled trial of intravenous nafamostat mesylate in COVID pneumonitis: Phase 1b/2a experimental study to investigate safety, Pharmacokinetics and Pharmacodynamics

Autor: Tom M. Quinn, Erin E. Gaughan, Annya Bruce, Jean Antonelli, Richard O'Connor, Feng Li, Sarah McNamara, Oliver Koch, Claire MacKintosh, David Dockrell, Timothy Walsh, Kevin G. Blyth, Colin Church, Jürgen Schwarze, Cecilia Boz, Asta Valanciute, Matthew Burgess, Philip Emanuel, Bethany Mills, Giulia Rinaldi, Gareth Hardisty, Ross Mills, Emily Gwyer Findlay, Sunny Jabbal, Andrew Duncan, Sinéad Plant, Adam D.L. Marshall, Irene Young, Kay Russell, Emma Scholefield, Alastair F. Nimmo, Islom B. Nazarov, Grant C. Churchill, James S.O. McCullagh, Kourosh H. Ebrahimi, Colin Ferrett, Kate Templeton, Steve Rannard, Andrew Owen, Anne Moore, Keith Finlayson, Manu Shankar-Hari, John Norrie, Richard A. Parker, Ahsan R. Akram, Daniel C. Anthony, James W. Dear, Nik Hirani, Kevin Dhaliwal

Publikováno v: EBioMedicine, Vol 76, Iss , Pp 103856- (2022)

Summary: Background: Many repurposed drugs have progressed rapidly to Phase 2 and 3 trials in COVID19 without characterisation of Pharmacokinetics /Pharmacodynamics including safety data. One such drug is nafamostat mesylate. Methods: We present the

Externí odkaz: https://doaj.org/article/30aabc317f5544bcb011f0340db28762

An Inhaled Galectin-3 Inhibitor in COVID-19 Pneumonitis (DEFINE):A Phase Ib/IIa Randomised Controlled Trial

Autor: Erin E, Gaughan, Tom M, Quinn, Andrew, Mills, Annya M, Bruce, Jean, Antonelli, Alison, MacKinnon, Vassilios, Aslanis, Feng, Li, Richard, O'Connor, Cecilia, Boz, Ross, Mills, Philip, Emanuel, Matthew, Burgess, Giulia, Rinaldi, Asta, Valanciute, Bethany, Mills, Emma, Scholefield, Gareth, Hardisty, Emily, Gwyer Findlay, Richard A, Parker, John, Norrie, James W, Dear, Ahsan R, Akram, Oliver, Koch, Kate, Templeton, David H, Dockrell, Timothy S, Walsh, Stephen, Partridge, Duncan, Humphries, Jie, Wang-Jairaj, Robert J, Slack, Hans, Schambye, De, Phung, Lise, Gravelle, Bertil, Lindmark, Manu, Shankar-Hari, Nikhil, Hirani, Tariq, Sethi, Kevin, Dhaliwal

Publikováno v: Gaughan, E E, Quinn, T M, Mills, A, Bruce, A M, Antonelli, J, Mackinnon, A, Aslanis, V, Li, F, O'connor, R, Boz, C, Mills, R, Emanuel, P, Burgess, M, Rinaldi, G, Valanciute, A, Mills, B, Scholefield, E, Hardisty, G, Gwyer Findlay, E, Parker, R A, Norrie, J, Dear, J W, Akram, A R, Koch, O, Templeton, K, Dockrell, D H, Walsh, T S, Partridge, S, Humphries, D, Wang-jairaj, J, Slack, R J, Schambye, H, Phung, D, Gravelle, L, Lindmark, B, Shankar-Hari, M, Hirani, N, Sethi, T & Dhaliwal, K 2022, ' An Inhaled Galectin-3 Inhibitor in COVID-19 Pneumonitis (DEFINE) : A Phase Ib/IIa Randomised Controlled Trial ', American Journal of Respiratory and Critical Care Medicine . https://doi.org/10.1164/rccm.202203-0477OC

Rationale: High circulating galectin-3 is associated with poor outcomes in patients with COVID-19. We hypothesised that GB0139, a potent inhaled thiodigalactoside galectin-3 inhibitor with anti-inflammatory and antifibrotic actions, would be safely a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::4cbdceb9f003b857818278fa3a4d79ec
https://www.pure.ed.ac.uk/ws/files/298426001/rccm.202203_0477oc_1_.pdf

Emerging Investigators Highlight.

Publikováno v: American Journal of Respiratory & Critical Care Medicine; 1/15/2023, Vol. 207 Issue 2, px-xii, 3p